US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · IC - Interstitial Cystitis · Interstitial Cystitis · LIPO
LIPELLA PHARMACEUTICALS
LIPELLA PHARMACEUTICALS INC.
LIPELLA PHARMACEUTICALS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Pittsburgh, USA HQ
2005 Founded
3 Employees
Public company Type
LIPO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Pittsburgh, USA
- Founded
- 2005
- Employees
- 3
- Programs
- 4
- Drugs
- 3
- Patents
- 4
LIPELLA PHARMACEUTICALS pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LIPELLA PHARMACEUTICALS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
ferumoxytol
Blood and blood forming organs (B03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor